Academic-industrial partnerships in drug discovery in the age of genomics

Tim Harris; Stelios Papadopoulos; David B Goldstein

doi:10.1016/j.tibtech.2015.02.009

Academic-industrial partnerships in drug discovery in the age of genomics

Trends Biotechnol. 2015 Jun;33(6):320-2. doi: 10.1016/j.tibtech.2015.02.009.

Authors

Tim Harris¹, Stelios Papadopoulos², David B Goldstein³

Affiliations

¹ Biogen, 225 Binney Street, Cambridge, MA 02142, USA. Electronic address: tim.harris@biogen.com.
² Biogen, 225 Binney Street, Cambridge, MA 02142, USA.
³ Institute for Genomic Medicine, Columbia University Medical Center, New York, NY 10032, USA.

PMID: 25987446
DOI: 10.1016/j.tibtech.2015.02.009

Abstract

Many US FDA-approved drugs have been developed through productive interactions between the biotechnology industry and academia. Technological breakthroughs in genomics, in particular large-scale sequencing of human genomes, is creating new opportunities to understand the biology of disease and to identify high-value targets relevant to a broad range of disorders. However, the scale of the work required to appropriately analyze large genomic and clinical data sets is challenging industry to develop a broader view of what areas of work constitute precompetitive research.

Keywords: academic collaborations; drug discovery; genomics.

MeSH terms

Academies and Institutes / trends
Biotechnology / trends
Drug Discovery / trends*
Drug Industry / trends*
Genome, Human*
Genomics
High-Throughput Nucleotide Sequencing*
Humans
Research / trends